BPC-157 vs GHK-Cu
A peptide sold to heal tendons, muscles and the gut. It has been tested mostly in rats, and the only human report covers 12 patients. A copper-based ingredient sold in skin creams and injections for wrinkles, hair loss and healing. It speeds wound healing in rats, but no proper human trial exists.
Both sit at grade C: animal and cell studies. Neither is FDA approved.
Evidence
CAnimal and cell studies
CAnimal and cell studies
Human studies cited
Animal or cell studies cited
Why the grade
A 2025 systematic review found 36 studies of BPC-157 for musculoskeletal injury: 35 preclinical, almost all in rats from one Zagreb research group, and one retrospective human series of 12 patients with knee pain. No randomized or controlled human trial has been published, so the healing claims rest on animal data (grade C). A second review, searching to June 2026, found nothing new.
For skin repair and wound healing, the use GHK-Cu is best known for, the primary studies in hand are cell cultures and rat and mouse experiments, including a hair-growth study in fuzzy rats. The human cosmetic results that reviews describe come from manufacturer-run tests that are summarised and not published in full, so no controlled human trial with a known sample size can be named.
FDA
Not approved
BPC-157 is not approved by the FDA for any use and is sold as a research chemical. On 28 October 2026 HHS issued an enforcement discretion policy. Under it, HHS will not act against state-licensed pharmacies and physicians that compound BPC-157 acetate for a named patient, by injection, by mouth or on the skin, if they meet sourcing, testing, labeling and reporting conditions. The policy is not an approval and does not add BPC-157 to the 503A bulks list. It lasts until a final rule settles that question.
Not approved
GHK-Cu is not approved by the FDA for any use. As copper tripeptide-1 it is sold in cosmetics, which sit outside FDA drug approval. The FDA placed the injectable form in Category 2 of its compounding list in 2023 over safety risks, and the agency now lists that nomination as withdrawn; it plans to bring GHK-Cu before its Pharmacy Compounding Advisory Committee by the end of February 2027.
Sold for
BPC-157 is sold as a healing peptide for tendons, ligaments, muscle and gut, taken by injection or orally, and is one of the most popular compounds in the grey-market peptide trade.
GHK-Cu is sold as an anti-aging and wound-healing peptide, in serums for wrinkles and hair thinning and as an injectable for recovery.
Studies say
Dozens of rat studies, nearly all from one laboratory, show faster tendon, ligament and gut healing, but the only human data are a 12-patient uncontrolled series, so nothing is established in people (grade C).
Cell and animal work shows that GHK-Cu raises collagen production and speeds wound closure in rats, but the human evidence is limited to cosmetic tests reported inside reviews, which is why the grade is C.
Class
Synthetic pentadecapeptide (gastric-derived)
Copper-binding tripeptide
Route
Several routes
Several routes